HR+ Metastatic Breast Cancer

Video

HR+ Metastatic Breast Cancer

Case: A 58-Year-Old Woman With Metastatic ER+ Ductal Carcinoma

  • 58-year-old woman with estrogen-receptor-positive (ER+), progesterone-receptor-negative (PR-), HER2-negative (HER2-) invasive ductal carcinoma (IDC) of L breast; she completed adjuvant anastrozole for 5 years
  • Now, 13 months later, she presents with 4 small (<1.0 cm) asymptomatic lesions in the left lung and mediastinal and hilar lymphadenopathy.
  • Mediastinoscopy was performed and confirmed ER+ PR- Her2- carcinoma
  • ECOG PS: 0
  • The patient was started on abemaciclib + fulvestrant
Related Videos
Video 6 - "Quality of Life + Clinical Monitoring Outside the Transplant Center"
Video 5 - "Second-Line Medications and Toxicities in GVHD"
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Related Content
Adding Entinostat to ICI Dual Therapy Delivers Promising Responses in TNBC

Adding Entinostat to ICI Dual Therapy Delivers Promising Responses in TNBC

April 30th 2024
Article

Although immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast cancer settings has fallen short.

Read More

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

Unpacking the New Recommendations for Early-Stage Breast Cancer Management

April 15th 2022
Podcast

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

Listen

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

April 22nd 2024
Article

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

Read More

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss

September 25th 2020
Podcast

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

Listen

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Read More

UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC

UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC

April 8th 2024
Article

During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.

Read More